应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
INBX Inhibrx Biosciences
交易中 07-18 15:26:27 EDT
13.03
-0.88
-6.36%
最高
13.87
最低
12.96
成交量
16.50万
今开
13.80
昨收
13.91
日振幅
6.51%
总市值
1.89亿
流通市值
1.59亿
总股本
1,448万
成交额
219.38万
换手率
1.35%
流通股本
1,223万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Inhibrx Biosciences, Inc.盘中异动 大幅跳水5.14%报13.67美元
自选股智能写手 · 07-18 00:29
Inhibrx Biosciences, Inc.盘中异动 大幅跳水5.14%报13.67美元
Inhibrx Biosciences, Inc.盘中异动 临近午盘急速下挫5.02%报12.77美元
自选股智能写手 · 07-05
Inhibrx Biosciences, Inc.盘中异动 临近午盘急速下挫5.02%报12.77美元
Inhibrx Biosciences, Inc.盘中异动 急速拉升5.11%报15.23美元
自选股智能写手 · 06-21
Inhibrx Biosciences, Inc.盘中异动 急速拉升5.11%报15.23美元
Inhibrx Biosciences, Inc.盘中异动 早盘股价大跌5.28%报13.80美元
自选股智能写手 · 06-20
Inhibrx Biosciences, Inc.盘中异动 早盘股价大跌5.28%报13.80美元
Inhibrx Biosciences, Inc.盘中异动 股价大跌5.03%报14.91美元
自选股智能写手 · 06-17
Inhibrx Biosciences, Inc.盘中异动 股价大跌5.03%报14.91美元
Inhibrx Biosciences, Inc.盘中异动 临近收盘股价大跌5.12%
自选股智能写手 · 06-15
Inhibrx Biosciences, Inc.盘中异动 临近收盘股价大跌5.12%
Inhibrx Biosciences, Inc.盘中异动 早盘急速拉升5.91%
自选股智能写手 · 06-07
Inhibrx Biosciences, Inc.盘中异动 早盘急速拉升5.91%
Inhibrx Biosciences, Inc.盘中异动 下午盘急速拉升5.05%报17.07美元
自选股智能写手 · 06-04
Inhibrx Biosciences, Inc.盘中异动 下午盘急速拉升5.05%报17.07美元
Inhibrx, Inc.股价飙升11.36% 市值涨2.03亿美元
自选股智能写手 · 05-30
Inhibrx, Inc.股价飙升11.36% 市值涨2.03亿美元
Inhibrx Inc. 股东批准向赛诺菲出售Inbrx-101
智通财经 · 05-25
Inhibrx Inc. 股东批准向赛诺菲出售Inbrx-101
Inhibrx Inc 预计每股亏损 1.04 美元 - 财报前瞻
Reuters · 05-03
Inhibrx Inc 预计每股亏损 1.04 美元 - 财报前瞻
Inhibrx, Inc.盘中异动 早盘股价大跌5.82%报34.33美元
自选股智能写手 · 03-04
Inhibrx, Inc.盘中异动 早盘股价大跌5.82%报34.33美元
Inhibrx 公司报告截至 12 月的季度业绩 - 收益摘要
Reuters · 03-04
Inhibrx 公司报告截至 12 月的季度业绩 - 收益摘要
Inhibrx Inc 预计每股亏损 1.04 美元 - 财报前瞻
Reuters · 03-01
Inhibrx Inc 预计每股亏损 1.04 美元 - 财报前瞻
美国研究综述-Inhibrx、LSB Industries、Xencor
Reuters · 02-29
美国研究综述-Inhibrx、LSB Industries、Xencor
Inhibrx Inc盘中异动 快速跳水5.21%
自选股智能写手 · 02-28
Inhibrx Inc盘中异动 快速跳水5.21%
Inhibrx Inc盘中异动 股价大涨6.53%
自选股智能写手 · 01-23
Inhibrx Inc盘中异动 股价大涨6.53%
今日优惠-合并与收购
Reuters · 01-23
今日优惠-合并与收购
赛诺菲(SNY)宣布收购Inhibrx(INBX),将纳入INBRX-101资产
金吾资讯 · 01-23
赛诺菲(SNY)宣布收购Inhibrx(INBX),将纳入INBRX-101资产
BUZZ-Inhibrx 因赛诺菲以约 22 亿美元收购罕见病药物项目而获利
Reuters · 01-23
BUZZ-Inhibrx 因赛诺菲以约 22 亿美元收购罕见病药物项目而获利
公司概况
公司名称:
Inhibrx Biosciences
所属市场:
NASDAQ
上市日期:
--
主营业务:
Inhibrx Biosciences, Inc.于2024年1月8日根据特拉华州法律成立,是Inhibrx, Inc.的直接全资子公司。该公司是一家临床阶段的生物制药公司,拥有一系列新型候选生物治疗药物,使用其专有的模块化蛋白质工程平台开发。
发行价格:
--
{"stockData":{"symbol":"INBX","market":"US","secType":"STK","nameCN":"Inhibrx Biosciences","latestPrice":13.025,"timestamp":1721330779769,"preClose":13.91,"halted":0,"volume":164980,"delay":0,"floatShares":12230000,"shares":14475904,"eps":0,"marketStatus":"交易中","marketStatusCode":2,"change":-0.885,"latestTime":"07-18 15:26:27 EDT","open":13.8,"high":13.865,"low":12.96,"amount":2193784.26452,"amplitude":0.065061,"askPrice":13.09,"askSize":190,"bidPrice":13.02,"bidSize":93,"shortable":3,"etf":0,"ttmEps":0,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721332800000},"adr":0,"adjPreClose":13.91,"postHourTrading":{"tag":"盘后","latestPrice":13.91,"preClose":13.91,"latestTime":"16:29 EDT","volume":1693,"amount":23551.33,"timestamp":1721248164558},"volumeRatio":1.563549,"impliedVol":0.1543,"impliedVolPercentile":0.0362},"requestUrl":"/m/hq/s/INBX/wiki","defaultTab":"wiki","newsList":[{"id":"2452616254","title":"Inhibrx Biosciences, Inc.盘中异动 大幅跳水5.14%报13.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452616254","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452616254?lang=zh_cn&edition=full","pubTime":"2024-07-18 00:29","pubTimestamp":1721233795,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日00时29分,Inhibrx Biosciences, Inc.股票出现异动,股价大幅跳水5.14%。截至发稿,该股报13.67美元/股,成交量4.1507万股,换手率0.29%,振幅5.20%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为2.00%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,拥有一系列新型生物治疗候选药物,这些药物是使用其专有的模块化蛋白质工程平台而被开发出来的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718002955aefa2906&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718002955aefa2906&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2449294395","title":"Inhibrx Biosciences, Inc.盘中异动 临近午盘急速下挫5.02%报12.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449294395","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449294395?lang=zh_cn&edition=full","pubTime":"2024-07-05 23:36","pubTimestamp":1720193779,"startTime":"0","endTime":"0","summary":"北京时间2024年07月05日23时36分,Inhibrx Biosciences, Inc.股票出现波动,股价急速下挫5.02%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.95%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,拥有一系列新型生物治疗候选药物,这些药物是使用其专有的模块化蛋白质工程平台而被开发出来的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705233619aef8302b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705233619aef8302b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2445765362","title":"Inhibrx Biosciences, Inc.盘中异动 急速拉升5.11%报15.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445765362","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445765362?lang=zh_cn&edition=full","pubTime":"2024-06-21 22:08","pubTimestamp":1718978910,"startTime":"0","endTime":"0","summary":"北京时间2024年06月21日22时08分,Inhibrx Biosciences, Inc.股票出现异动,股价急速拉升5.11%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.31%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,拥有一系列新型生物治疗候选药物,这些药物是使用其专有的模块化蛋白质工程平台而被开发出来的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240621220830941f0233&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240621220830941f0233&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2444212962","title":"Inhibrx Biosciences, Inc.盘中异动 早盘股价大跌5.28%报13.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444212962","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444212962?lang=zh_cn&edition=full","pubTime":"2024-06-20 21:42","pubTimestamp":1718890936,"startTime":"0","endTime":"0","summary":"北京时间2024年06月20日21时42分,Inhibrx Biosciences, Inc.股票出现波动,股价大幅下挫5.28%。截至发稿,该股报13.80美元/股,成交量1.1767万股,换手率0.08%,振幅4.47%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.13%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,拥有一系列新型生物治疗候选药物,这些药物是使用其专有的模块化蛋白质工程平台而被开发出来的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240620214216968157eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240620214216968157eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2444984871","title":"Inhibrx Biosciences, Inc.盘中异动 股价大跌5.03%报14.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444984871","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444984871?lang=zh_cn&edition=full","pubTime":"2024-06-17 22:01","pubTimestamp":1718632870,"startTime":"0","endTime":"0","summary":"北京时间2024年06月17日22时01分,Inhibrx Biosciences, Inc.股票出现异动,股价快速下跌5.03%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.74%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,拥有一系列新型生物治疗候选药物,这些药物是使用其专有的模块化蛋白质工程平台而被开发出来的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240617220110af8de3d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240617220110af8de3d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2443022276","title":"Inhibrx Biosciences, Inc.盘中异动 临近收盘股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2443022276","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443022276?lang=zh_cn&edition=full","pubTime":"2024-06-15 03:45","pubTimestamp":1718394349,"startTime":"0","endTime":"0","summary":"北京时间2024年06月15日03时45分,Inhibrx Biosciences, Inc.股票出现异动,股价快速跳水5.12%。截至发稿,该股报15.74美元/股,成交量15.1009万股,换手率1.04%,振幅5.24%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.04%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,拥有一系列新型生物治疗候选药物,这些药物是使用其专有的模块化蛋白质工程平台而被开发出来的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240615034549af8da6fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240615034549af8da6fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2441671770","title":"Inhibrx Biosciences, Inc.盘中异动 早盘急速拉升5.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441671770","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441671770?lang=zh_cn&edition=full","pubTime":"2024-06-07 23:05","pubTimestamp":1717772719,"startTime":"0","endTime":"0","summary":"北京时间2024年06月07日23时05分,Inhibrx Biosciences, Inc.股票出现波动,股价急速拉升5.91%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.34%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,拥有一系列新型生物治疗候选药物,这些药物是使用其专有的模块化蛋白质工程平台而被开发出来的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240607230519aef4141c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240607230519aef4141c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2440195314","title":"Inhibrx Biosciences, Inc.盘中异动 下午盘急速拉升5.05%报17.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440195314","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440195314?lang=zh_cn&edition=full","pubTime":"2024-06-04 02:18","pubTimestamp":1717438715,"startTime":"0","endTime":"0","summary":"北京时间2024年06月04日02时18分,Inhibrx Biosciences, Inc.股票出现波动,股价快速上涨5.05%。截至发稿,该股报17.07美元/股,成交量25.0908万股,换手率1.76%,振幅4.52%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为1.22%。Inhibrx Biosciences, Inc.公司简介:Inhibrx Biosciences Inc是一家临床阶段的生物制药公司,拥有一系列新型生物治疗候选药物,这些药物是使用其专有的模块化蛋白质工程平台而被开发出来的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406040218359681191e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406040218359681191e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2439640710","title":"Inhibrx, Inc.股价飙升11.36% 市值涨2.03亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439640710","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439640710?lang=zh_cn&edition=full","pubTime":"2024-05-30 22:01","pubTimestamp":1717077661,"startTime":"0","endTime":"0","summary":"北京时间2024年05月30日22时01分,Inhibrx, Inc.股票出现异动,股价快速上涨11.36%。截至发稿,该股报34.11美元/股,成交量0股,换手率0.00%,振幅0.00%。Inhibrx, Inc.股票所在的生物技术行业中,整体跌幅为0.25%。Inhibrx, Inc.公司简介:Inhibrx Inc是一家临床阶段的生物技术公司,致力于开发一种新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405302201029f05a9b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405302201029f05a9b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2438370098","title":"Inhibrx Inc. 股东批准向赛诺菲出售Inbrx-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2438370098","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438370098?lang=zh_cn&edition=full","pubTime":"2024-05-25 04:05","pubTimestamp":1716581134,"startTime":"0","endTime":"0","summary":"Inhibrx Inc. 股东批准向赛诺菲出售Inbrx-101","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405250405369ee4931f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405250405369ee4931f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2432971532","title":"Inhibrx Inc 预计每股亏损 1.04 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432971532","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432971532?lang=zh_cn&edition=full","pubTime":"2024-05-03 20:32","pubTimestamp":1714739559,"startTime":"0","endTime":"0","summary":" * Inhibrx Inc 预计将在5月6日公布截至2024年3月31日的业绩报告(预计),季度收入将有所增长。* LSEG 分析师对 Inhibrx 公司的平均预期是每股亏损 1.04 美元。* 目前,分析师对该公司股票的平均评级为 \"持有\",建议分类为无 \"强力买入 \"或 \"买入\",3个 \"持有\",无 \"卖出 \"或 \"强力卖出\"。* 华尔街对 Inhibrx Inc 的 12 个月目标价中值为 35.50 美元,高于其 34.01 美元的最新收盘价。5月3日 - 本摘要于北京时间 5 月 3 日 12:32 机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX"],"gpt_icon":0},{"id":"2416914481","title":"Inhibrx, Inc.盘中异动 早盘股价大跌5.82%报34.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2416914481","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416914481?lang=zh_cn&edition=full","pubTime":"2024-03-04 22:31","pubTimestamp":1709562665,"startTime":"0","endTime":"0","summary":"北京时间2024年03月04日22时31分,Inhibrx, Inc.股票出现波动,股价快速下跌5.82%。截至发稿,该股报34.33美元/股,成交量6.4043万股,换手率0.14%,振幅0.00%。Inhibrx, Inc.股票所在的生物技术行业中,整体涨幅为0.56%。Inhibrx, Inc.公司简介:Inhibrx Inc是一家临床阶段的生物技术公司,致力于开发一种新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240304223105791718c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240304223105791718c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2416114823","title":"Inhibrx 公司报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2416114823","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416114823?lang=zh_cn&edition=full","pubTime":"2024-03-04 20:01","pubTimestamp":1709553674,"startTime":"0","endTime":"0","summary":" * Inhibrx Inc 报告,截至12月底的季度调整后每股亏损1.73美元,低于去年同期的每股收益-95美分。三位分析师对该季度的平均预期是每股亏损 1.04 美元。华尔街预期为每股亏损 1.08 美元至-98 美分。* 营收同比增长 496.4%,达到 163 万美元;分析师预期为 5 万美元。* Inhibrx Inc 公布的本季度每股收益为亏损 1.73 美元。* 该公司当季亏损 9360 万美元。* Inhibrx Inc 本季度股价下跌了 4.1%。华尔街对 Inhibrx 公司 12 个月目标价的中位数为 35.50 美元。本摘要由 LSEG 3 月 4 日 12:00 p.m. UTC 数据机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2416690708","title":"Inhibrx Inc 预计每股亏损 1.04 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2416690708","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416690708?lang=zh_cn&edition=full","pubTime":"2024-03-01 19:03","pubTimestamp":1709291015,"startTime":"0","endTime":"0","summary":" * Inhibrx Inc 预计将在5月6日公布截至2024年3月31日的业绩报告(预计),季度收入将有所增长。* LSEG 分析师对 Inhibrx 公司的平均预期是每股亏损 1.04 美元。* 目前,分析师对该公司股票的平均评级为 \"持有\",建议分类为无 \"强力买入 \"或 \"买入\",3个 \"持有\",无 \"卖出 \"或 \"强力卖出\"。* 华尔街对 Inhibrx Inc 的 12 个月目标价中位数为 35.50 美元,低于其最新收盘价 36.63 美元。除非另有说明,所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX"],"gpt_icon":0},{"id":"2415541152","title":"美国研究综述-Inhibrx、LSB Industries、Xencor","url":"https://stock-news.laohu8.com/highlight/detail?id=2415541152","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415541152?lang=zh_cn&edition=full","pubTime":"2024-02-29 20:56","pubTimestamp":1709211391,"startTime":"0","endTime":"0","summary":" 路透社2月29日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价,其中包括 Inhibrx、LSB Industries 和 Xencor。* Inhibrx Inc :杰富瑞将其评级从 \"买入 \"下调至 \"持有 * LSB Industries Inc :Piper Sandler将其评级从 \"中性 \"下调至 \"减持\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4187","AMH","BAND","ALKT","AVIR","BCSF","ACMR","ACLX","BK4154","BE","SAM","AGL","AAP","BXSL","BK4182","ATSG","IE00BZ1G4Q59.USD","ADP","APG","AZO","BBDC","ACHC","AXON","LU0965509101.SGD","INBX","BRP","ARVN","APA","ABNB","ARRY","ASPI","BKNG","MITT","LU0266013472.USD","AMP","AEO","AMRC","COLD","AI","BYND","AVDX","LU0234570918.USD","BK4224","BK4543","BGS","DIBS","ALHC","ARKO","BK4185","BK4089"],"gpt_icon":0},{"id":"2415371595","title":"Inhibrx Inc盘中异动 快速跳水5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2415371595","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2415371595?lang=zh_cn&edition=full","pubTime":"2024-02-28 23:57","pubTimestamp":1709135851,"startTime":"0","endTime":"0","summary":"北京时间2024年02月28日23时57分,Inhibrx Inc股票出现异动,股价急速下挫5.21%。Inhibrx Inc股票所在的生物技术行业中,整体跌幅为0.46%。其相关个股中,Vivani Medical Inc、Adial Pharmaceuticals Inc、Vtv Therapeutics Inc涨幅较大,Adial Pharmaceuticals Inc、Vivani Medical Inc、Zyversa Therapeutics Inc较为活跃,换手率分别为3423.96%、179.60%、77.55%,振幅较大的相关个股有Vivani Medical Inc、Adial Pharmaceuticals Inc、Ys Biopharma Co Ltd C/Wts 15/03/2028 ,振幅分别为339.60%、199.23%、92.30%。Inhibrx Inc公司简介:Inhibrx Inc是一家临床阶段的生物技术公司,致力于开发一种新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402282357327a47c7b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402282357327a47c7b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2405412290","title":"Inhibrx Inc盘中异动 股价大涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2405412290","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2405412290?lang=zh_cn&edition=full","pubTime":"2024-01-23 22:31","pubTimestamp":1706020317,"startTime":"0","endTime":"0","summary":"北京时间2024年01月23日22时31分,Inhibrx Inc股票出现异动,股价大幅上涨6.53%。Inhibrx Inc股票所在的生物技术行业中,整体跌幅为0.22%。其相关个股中,Evaxion Biotech As、Ensysce Biosciences Inc、Outlook Therapeutics Inc涨幅较大,Ensysce Biosciences Inc、Panbela Therapeutics Inc、Transcode Therapeutics Inc较为活跃,换手率分别为212.32%、10.98%、8.25%,振幅较大的相关个股有Evaxion Biotech As、Ensysce Biosciences Inc、Igc Pharma Inc,振幅分别为15.57%、9.65%、9.31%。Inhibrx Inc公司简介:Inhibrx Inc是一家临床阶段的生物技术公司,致力于开发一种新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012322315787dabafc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012322315787dabafc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2405499981","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2405499981","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2405499981?lang=zh_cn&edition=full","pubTime":"2024-01-23 19:03","pubTimestamp":1706007808,"startTime":"0","endTime":"0","summary":"** 印度泰米尔纳德邦表示,康宁 的一家合资企业同意投资100亿卢比,凸显了这个南亚国家作为制造业中心日益增长的重要性。** 印度Zee娱乐 股价暴跌30%之多,创下有史以来最糟糕的一天,此前该公司与索尼本地部门的100亿美元并购案告吹,引发了人们对该公司将无法茁壮成长的担忧。** Bridgepoint 宣布收购抗衰老化妆品集团RoC,证实了路透早些时候的报道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4148","BK4139","00656","BK4588","BK1230","BK4585","BK4512","INBX","BK4135","GLW","ABG.AU","BK7154","LU0348723411.USD","CG"],"gpt_icon":0},{"id":"2405145065","title":"赛诺菲(SNY)宣布收购Inhibrx(INBX),将纳入INBRX-101资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2405145065","media":"金吾资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2405145065?lang=zh_cn&edition=full","pubTime":"2024-01-23 18:38","pubTimestamp":1706006289,"startTime":"0","endTime":"0","summary":"金吾财讯 | 赛诺菲(SNY)在官网宣布与生物制药上市公司Inhibrx(INBX)达成一项最终协议,根据该协议,赛诺菲同意在将非INBRX-101资产分拆并入新Inhibrx公司后收购Inhibrx。根据协议,Inhibrx公司股东每持有一股Inhibrx股票,将获得30.0美元现金、5.0美元或有价值权(CVR)和0.25股新上市公司股份,新上市公司将保留Inhibrx的非INBRX-101资产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012318383881dacd21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012318383881dacd21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX","BK4585","SNY","BK4007","BK4588"],"gpt_icon":0},{"id":"2405214317","title":"BUZZ-Inhibrx 因赛诺菲以约 22 亿美元收购罕见病药物项目而获利","url":"https://stock-news.laohu8.com/highlight/detail?id=2405214317","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2405214317?lang=zh_cn&edition=full","pubTime":"2024-01-23 18:15","pubTimestamp":1706004924,"startTime":"0","endTime":"0","summary":" 1月23日 - ** Inhibrx 股价盘前上涨6.9%至35.62美元** 法国医疗保健公司赛诺菲 已同意 ,以约22亿美元收购Inhibrx的药物开发项目INBRX-101,以促进其罕见病业务的发展。** Cos公司称,INBX公司的股东将获得每股30美元的现金、一项相当于5美元的或有价值权,以及0.25股新Inhibrx公司的股份,新Inhibrx公司是一家新的上市公司,持有收购目标公司与INBRX-101无关的资产。** INBRX-101 目前处于三期临床试验的第二期,正在开发用于治疗一种导致肺组织进行性恶化的遗传性罕见疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX","BUZZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inhibrx.com","stockEarnings":[{"period":"1week","weight":0.0725},{"period":"1month","weight":-0.0197},{"period":"3month","weight":-0.1306},{"period":"ytd","weight":-0.1306}],"compareEarnings":[{"period":"1week","weight":-0.0078},{"period":"1month","weight":0.018},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1544},{"period":"1year","weight":0.2262},{"period":"ytd","weight":0.1717}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Inhibrx Biosciences, Inc.于2024年1月8日根据特拉华州法律成立,是Inhibrx, Inc.的直接全资子公司。该公司是一家临床阶段的生物制药公司,拥有一系列新型候选生物治疗药物,使用其专有的模块化蛋白质工程平台开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.100441},{"month":2,"riseRate":0,"avgChangeRate":-0.118883},{"month":3,"riseRate":0.25,"avgChangeRate":-0.108872},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034815},{"month":5,"riseRate":0.25,"avgChangeRate":-0.039218},{"month":6,"riseRate":0.666667,"avgChangeRate":0.088726},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111417},{"month":8,"riseRate":1,"avgChangeRate":0.030836},{"month":9,"riseRate":0.75,"avgChangeRate":0.016607},{"month":10,"riseRate":0.5,"avgChangeRate":0.197255},{"month":11,"riseRate":0.75,"avgChangeRate":0.223807},{"month":12,"riseRate":0.75,"avgChangeRate":0.232405}],"exchange":"NASDAQ","name":"Inhibrx Biosciences","nameEN":"Inhibrx Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inhibrx Biosciences(INBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inhibrx Biosciences,INBX,Inhibrx Biosciences股票,Inhibrx Biosciences股票老虎,Inhibrx Biosciences股票老虎国际,Inhibrx Biosciences行情,Inhibrx Biosciences股票行情,Inhibrx Biosciences股价,Inhibrx Biosciences股市,Inhibrx Biosciences股票价格,Inhibrx Biosciences股票交易,Inhibrx Biosciences股票购买,Inhibrx Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inhibrx Biosciences(INBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}